[Hearing loss caused by high dose carboplatin therapy].
BACKGROUND
Carboplatin is regarded as a non-ototoxic or low-grade ototoxic chemotherapeutic agent.


METHODS
We report on three patients with a recurrence of testicular cancer after cisplatin chemotherapy who suffered hearing loss after subsequent high-dose carboplatin therapy.


RESULTS
Audiometry demonstrated carboplatin-induced hearing loss primarily in the mid-range and high frequencies up to 45 dB at 3 kHz and up to 55 dB at 8 kHz. In two of three patients, transitory-evoked otoacoustic emissions were absent after carboplatin therapy.


CONCLUSIONS
Following first-line cisplatin chemotherapy, salvage treatment with high-dose carboplatin can generate hearing loss in the middle and high frequencies.
Lautermann
J
J
Universitäts-Hals-Nasen-Ohrenklinik Essen.
Adamczyk
M
M
ten Cate
W J
WJ
Kloke
O
O
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold / Q000187:drug effects; D001844:Bone Conduction / Q000187:drug effects; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006314:Hearing Loss, Conductive / Q000139:chemically induced* / Q000175:diagnosis; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced / Q000175:diagnosis; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017084:Otoacoustic Emissions, Spontaneous / Q000187:drug effects; D016879:Salvage Therapy; D013736:Testicular Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D016190:Carboplatin; D002945:Cisplatin